These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effect of sucralfate on the degradation of human gastric mucus by Helicobacter pylori protease and lipases. Slomiany BL; Piotrowski J; Slomiany A Am J Gastroenterol; 1992 May; 87(5):595-9. PubMed ID: 1595646 [TBL] [Abstract][Full Text] [Related]
6. Colloidal bismuth subcitrate inhibits peptic degradation of gastric mucus and epidermal growth factor in vitro. Slomiany BL; Nishikawa H; Bilski J; Slomiany A Am J Gastroenterol; 1990 Apr; 85(4):390-3. PubMed ID: 2109526 [TBL] [Abstract][Full Text] [Related]
7. Ebrotidine effect on the proteolytic and lipolytic activities of Helicobacter pylori. Slomiany BL; Piotrowski J; Mojtahed H; Slomiany A Gen Pharmacol; 1992 Mar; 23(2):203-6. PubMed ID: 1639232 [TBL] [Abstract][Full Text] [Related]
11. The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori. Vogt K; Warrelmann M; Hahn H Zentralbl Bakteriol; 1989 Sep; 271(3):304-10. PubMed ID: 2803458 [TBL] [Abstract][Full Text] [Related]
12. Review of the modes of action of colloidal bismuth subcitrate. Hall DW Scand J Gastroenterol Suppl; 1989; 157():3-6; discussion 21-2. PubMed ID: 2665050 [TBL] [Abstract][Full Text] [Related]
13. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Marshall BJ; Armstrong JA; Francis GJ; Nokes NT; Wee SH Digestion; 1987; 37 Suppl 2():16-30. PubMed ID: 3622946 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of Helicobacter pylori pathogenesis: focus on mucus. Slomiany BL; Slomiany A J Clin Gastroenterol; 1992; 14 Suppl 1():S114-21. PubMed ID: 1378466 [TBL] [Abstract][Full Text] [Related]
15. Evidence for weakening of gastric mucus integrity by Campylobacter pylori. Sarosiek J; Slomiany A; Slomiany BL Scand J Gastroenterol; 1988 Jun; 23(5):585-90. PubMed ID: 3399831 [TBL] [Abstract][Full Text] [Related]
16. Non-ulcer dyspepsia and short term De-Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori. Rokkas T; Pursey C; Uzoechina E; Dorrington L; Simmons NA; Filipe MI; Sladen GE Gut; 1988 Oct; 29(10):1386-91. PubMed ID: 3058555 [TBL] [Abstract][Full Text] [Related]
17. Morphologic evaluation of gastric mucosal protection by colloidal bismuth subcitrate (De-Nol). van den Hoven WE; Birtwhistle RD; Hall DW Int J Tissue React; 1988; 10(5):297-304. PubMed ID: 3250943 [TBL] [Abstract][Full Text] [Related]
18. Colloidal bismuth subcitrate evokes adaptive cytoprotection in rat gastric mucosa. Balint GA Acta Med Hung; 1991; 48(3-4):197-201. PubMed ID: 1822857 [TBL] [Abstract][Full Text] [Related]
19. Gastric mucosa protective effects of colloidal bismuth subcitrate (DE-NOL). Hall DW; van den Hoven WE Int J Tissue React; 1987; 9(5):427-32. PubMed ID: 3478321 [TBL] [Abstract][Full Text] [Related]
20. Sensitivity of Campylobacter pylori to colloidal bismuth subcitrate. Goodwin CS; Bell B; McCullough C; Turner M J Clin Pathol; 1989 Feb; 42(2):216-7. PubMed ID: 2921366 [No Abstract] [Full Text] [Related] [Next] [New Search]